Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (34-DAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01373333

Recruitment Status : No longer available

First Posted : June 14, 2011

Last Update Posted : July 20, 2016

Sponsor:

Information provided by (Responsible Party):

The Cleveland Clinic

Study Details
Tabular View
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	No longer available
Estimated Primary Completion Date :	September 2012
Study Completion Date :	No date given

To Top